Axios @axios
An 18-month congressional investigation found the FDA didn't follow its own guidance and inappropriately collaborated with drugmaker Biogen before the approval of a controversial Alzheimer's drug last year. https://t.co/pY7yiRBXHR — PolitiTweet.org